Abstract 387P
Background
The prevalence of tobacco use has significant implications for the global economy, since it is the leading cause of death and disease worldwide. Currently, tobacco-related factors contribute to an estimated 8 million deaths annually, with a majority of these fatalities concentrated in low- and middle-income countries. The objective of this study was to perform a thorough evaluation of existing literature concerning tobacco use and cancer prevalence across Indian tribal tribes, with the aim of ascertaining the prevalence, distribution, and factors that contribute to tobacco use, which is necessary for the purpose of developing and modifying control strategies aimed at mitigating tobacco consumption among this marginalized community.
Methods
A systematic review was undertaken to examine the available evidence on the oral health status, tobacco use, and cancer prevalence among tribal groups in India. The review was registered in the PROSPERO database. Sources published from 1980 to 2023 from reputable databases like PubMed, Crossref, Google Scholar, and Web of Science were used in this evaluation.
Results
The findings of this study encompass a comprehensive analysis of 22 distinct tribal population involving 28,572 individuals. The prevalence of tobacco consumption varied between 12% and 42.5%. In the context of gender-specific studies, the prevalence of tobacco use among females varied between 1.2% and 12%, whereas among males it ranged from 15% to 52%. The prevalence of oral cancer in this marginalized community ranged from 5% to 12%, as assessed. In contrast, the consumption of smokeless tobacco was prevalent throughout the indigenous community. The primary risk factors for tobacco use were identified as a dearth of information regarding oral health, deeply entrenched dental attitudes, and limited accessibility to health services.
Conclusions
To effectively address the issue of tobacco use, it is imperative to prioritize additional research on improved methodologies, evidence-based policies, and viable options for tobacco cessation. This review recommends implementing campaigns and abstinence as an effective strategy for mitigating the adverse consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract